N-(2-aminophenyl)-4-{3-chloro-5-[2-(dimethylamino)ethoxy]pyridin-2-yl}benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-aminophenyl)-4-{3-chloro-5-[2-(dimethylamino)ethoxy]pyridin-2-yl}benzamide
• 英文别名: N-(2-aminophenyl)-4-[3-chloro-5-[2-(dimethylamino)ethoxy]pyridin-2-yl]benzamide
• 化学式: C₂₂H₂₃ClN₄O₂
• 分子量: 410.903
• InChiKey: OOFYUCPHBXTXNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  80.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N,N-二甲基乙醇胺 、 N-(2-aminophenyl)-4-(3-chloro-5-hydroxypyridin-2-yl)benzamide 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以16%的产率得到N-(2-aminophenyl)-4-{3-chloro-5-[2-(dimethylamino)ethoxy]pyridin-2-yl}benzamide
  参考文献：
  名称：

  WO2006/75160

  摘要：

  公开号：

文献信息

• N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Gibson Keith Hopkinson

  公开号：US20100075942A1

  公开（公告）日：2010-03-25

  The invention concerns benzamide derivatives of Formula (I) wherein R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , W, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).

  本发明涉及公式（I）的苯甲酰胺衍生物，其中R1a、R1b、R1c、R2、R3、R4、W、m和n具有描述中定义的任何含义；它们的制备过程，含有它们的制药组合物以及它们在制造用作抗增殖剂的药物，用于预防或治疗对组蛋白去乙酰化酶（HDAC）抑制敏感的肿瘤或其他增殖性疾病。
• COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS
  申请人：Larsson Pia

  公开号：US20140051716A1

  公开（公告）日：2014-02-20

  There is provided a compound which is a histone deacetylase (HDAC) inhibitor, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for use in: (I) treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation; and/or (II) potentiating the degradation of fibrin deposits and preventing such deposits associated with pathological conditions or which may lead to such conditions, wherein the HDAC inhibitor, and the dose thereof, is as described in the description. There is also provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in improving or normalizing endogenous fibrinolysis impaired by local or systemic inflammation.
• [EN] N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE DERIVATIVES AS HISTONE DEACYLASE (HDAC) INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DERIVES DE N-PHENYL-4-PYRIDIN-2-YL-BENZAMIDE UTILISES COMME INHIBITEURS DE L'HISTONE DEACETYLASE (HDAC) POUR TRAITER LE CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2006075160A1

  公开（公告）日：2006-07-20

  [EN] The invention concerns benzamide derivatives of Formula (I) wherein R^1a, R^1b, R^1c, R², R³, R⁴, W, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).
  [FR] L'invention concerne des dérivés de benzamide représentés par la formule (I) dans laquelle R^1a, R^1b, R^1c, R², R³, R⁴, W, m et n ont les significations définies dans la description; leurs procédés de préparation; des compositions pharmaceutiques contenant lesdits dérivés; et leur utilisation pour produire un médicament utilisé comme agent antiprolifératif afin de prévenir ou de traiter des tumeurs ou autres états prolifératifs qui sont sensibles à l'inhibition de l'histone déacétylase (HDAC).
• WO2006/75160
  申请人：——

  公开号：——

  公开（公告）日：——